Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 752.43 USD -2.44% Market Closed
Market Cap: $79.1B

Net Margin

32.1%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
32.1%
=
Net Income
$4.6B
/
Revenue
$14.2B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
32.1%
=
Net Income
$4.6B
/
Revenue
$14.2B

Peer Comparison

Country Company Market Cap Net
Margin
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
111.6B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
82.4T KRW
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...

Market Distribution

Higher than 94% of companies in the United States of America
Percentile
94rd
Based on 15 072 companies
94rd percentile
32.1%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Regeneron Pharmaceuticals Inc
Glance View

In the vibrant world of biotechnology, Regeneron Pharmaceuticals Inc. emerged as a powerhouse by meticulously weaving together science and medicine. Founded in 1988 by a visionary team, including celebrated scientists Dr. Leonard Schleifer and Dr. George Yancopoulos, Regeneron was created with an ambitious mission to harness the power of biology to bring innovative medicines to patients. The company began its journey with a strong emphasis on research and development, evolving its unique approach to drug discovery focused on the rapid and precise identification of biologically relevant targets. With a strategic location at the heart of New York's biotechnology valley, Regeneron thrived, investing substantially in proprietary technologies and developing a robust pipeline of therapeutics aimed at addressing critical unmet medical needs across various domains such as ophthalmology, immunology, oncology, and rare diseases. Today, Regeneron makes its mark in the pharmaceutical industry primarily through its innovative product portfolio, comprised of renowned drugs like EYLEA, a leading treatment for retinal diseases, and Dupixent, a medication for atopic dermatitis and other allergic conditions. The company's revenue model relies heavily on the commercial success of these drugs, supported by strategic collaborations and partnerships with industry giants like Sanofi. Their success is driven by a commitment to leveraging cutting-edge technology platforms, such as the VelociSuite, which expedites drug discovery and development processes. Regeneron’s emphasis on precision and quality, coupled with an agile business model that adapts to health landscapes, allows it to maintain a competitive edge in a rapidly evolving industry while consistently delivering robust financial performance.

REGN Intrinsic Value
774.56 USD
Undervaluation 3%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
32.1%
=
Net Income
$4.6B
/
Revenue
$14.2B
What is Regeneron Pharmaceuticals Inc's current Net Margin?

The current Net Margin for Regeneron Pharmaceuticals Inc is 32.1%, which is in line with its 3-year median of 32.1%.

How has Net Margin changed over time?

Over the last 3 years, Regeneron Pharmaceuticals Inc’s Net Margin has decreased from 39.2% to 32.1%. During this period, it reached a low of 29.4% on Mar 31, 2024 and a high of 39.2% on Sep 30, 2022.

Back to Top